商业CAR-T细胞治疗后T细胞淋巴瘤及第二原发恶性肿瘤风险
报告一例非霍奇金B细胞淋巴瘤患者在接受抗CD19 CAR-T免疫治疗后3个月发生T细胞淋巴瘤,该T细胞克隆在CAR-T输注前血液和肺癌组织中已低水平存在。分析449例接受商业CAR-T(CD19、BCMA)治疗的患者,中位随访10.3个月,16例(3.6%)发生第二原发恶性肿瘤,仅观察到1例T细胞淋巴瘤,提示CAR-T后T细胞淋巴瘤风险较低。
要点
- 一例T细胞淋巴瘤在抗CD19 CAR-T治疗后3个月发生,携带JAK3变异和CD8+细胞毒性表型,CAR转基因水平很低。
- 该T细胞克隆在CAR-T输注前血液和肺癌中已低水平检出。
- 449例商业CAR-T治疗患者中,16例(3.6%)发生第二原发恶性肿瘤,仅1例T细胞淋巴瘤。
核心结论
- 在449例接受商业CAR-T(CD19、BCMA)治疗的患者中仅观察到1例T细胞淋巴瘤,提示CAR-T后T细胞淋巴瘤风险较低。
研究设计与样本
- 对宾夕法尼亚大学449例接受商业CAR-T(CD19、BCMA)治疗的患者进行第二原发恶性肿瘤风险分析,并报告一例CAR-T后T细胞淋巴瘤病例。
主要发现
- 一例非霍奇金B细胞淋巴瘤患者在接受抗CD19 CAR-T免疫治疗后3个月发生T细胞淋巴瘤,经肺癌手术时胸廓淋巴结诊断。
- 该T细胞淋巴瘤呈CD8+细胞毒性表型并携带JAK3变异,CAR转基因水平很低。
- 该T细胞克隆在CAR-T输注前血液中及肺癌中低水平检出。
- 中位随访10.3个月时,449例中16例(3.6%)发生第二原发恶性肿瘤。
- 实体瘤和血液系统恶性肿瘤的中位发生时间分别为26.4个月和9.7个月,预计5年累积发生率分别为15.2%和2.3%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report a T cell lymphoma (TCL) occurring 3 months after anti-CD19 chimeric antigen receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The TCL was diagnosed from a thoracic lymph node upon surgery for lung cancer. The TCL exhibited CD8+ cytotoxic phenotype and a JAK3 variant, while the CAR transgene was very low. The T cell clone was identified at low levels in the blood before CAR T infusion and in lung cancer. To assess the overall risk of secondary primary malignancy after commercial CAR T (CD19, BCMA), we analyzed 449 patients treated at the University of Pennsylvania. At a median follow-up of 10.3 months, 16 patients (3.6%) had a secondary primary malignancy. The median onset time was 26.4 and 9.7 months for solid and hematological malignancies, respectively. The projected 5-year cumulative incidence is 15.2% for solid and 2.3% for hematological malignancies. Overall, one case of TCL was observed, suggesting a low risk of TCL after CAR T.
引用
- Ghilardi G, Fraietta JA, Gerson JN, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med. 2024. PMID: 38266761. doi:10.1038/s41591-024-02826-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。